been working on this for a while: PsychedelicMarketCap.com if you're following #psychedelic stocks, this should help 📊🍄👩‍🔬

if you could only hold one psy stock for 5 years and not touch it, which one?

🍄🚀

the only site that treats psy stocks like real stocks → psymarketcap.com

psy bulls ride together 🍄🤝

we're early. painfully early. beautifully early.

DMT, psilocybin, or MDMA?

something's cooking in the sector 🔥

"i'll sell when it hits $X" .... famous last words

$DFTX seems unstoppable 👀

Hoping $DFTX will have a better MADRS score reduction than $CMPS although they were relatively close in their 2b comparisons, Definium achieving a placebo-adjusted reduction of 5.7 at week 4 compared to 6.6 at week 3 for Compass. Direct comparison is also not entirely applicable since Compass was Treatment-Resistant Depression while Definium is treating Major Depressive Disorder. Either way, Compass had a significant drop in their PH3 and Definium will not be different. Primary endpoint is Week 12 while Compass PH3 was Week 6 so that also seems indicative of something lower given trial data already shows reduction lowers as time goes by. If we do end up doing better and crush it with a reduction of 4.5 or better it wouldn’t surprise me about a big price jump. Worse than the Compass MADRS and I could see a solid slashing. It’s all hard to say. Either way, not long to wait now.

biotech bros or psychonauts — who's really driving this sector rn

🚨 NEW LISTING ALERT 🚨 $XTLB (XTL Biopharmaceuticals) has officially entered the psychedelic sector following its strategic acquisition of Psyga Bio! Which brings 7 Phase 2a programs focused on advanced psilocybin and ibogaine delivery. psychedelicmarketcap.com/sto…

The biggest catalyst in psychedelics is weeks away. $DFTX reports its first Phase 3 in late Q2. psychedelicmarketcap.com/blo…

Six-eight months ago $ATAI was #1, now it is #3. I suspect they will jump up once they announce PH3 initiation in the coming weeks and readouts get closer through 2027. Either way those are the big three, and give you a position in the three most relevant classical psychedelics (LSD/Psilocybin/DMT). All of them have a great thesis and are well-funded. The next couple years are going to surprise a lot of people. $DFTX $CMPS

$CMPS just took the second marketcap spot and flipped $ATAI. Psy season is on 🔥🚀

how much of your portfolio is in psy stocks? be honest

full list of publicly traded psy companies, sorted by market cap → psymarketcap.com

Spravato is almost 2 Billion a year in revenue. $CMPS has 135 mil outstanding shares. COMP360 is on pace for approval rollout 4th quarter this year. Even w/ ignoring possible PTSD approval in 2027 we are looking at a ~$60/share price. This is an incredible opportunity.

name a psychedelic stock that's undervalued right now

catalyst calendar: what's the next readout you care about?